CASP1 and rheumatoid arthritis: Of the compounds targeting caspase-1, VX-740 showed good anti-inflammatory performance in phase 1 and phase 2 trials for rheumatoid arthritis but the trials were discontinued due to drug-related hepatotoxicity.